Journal
EMERGING INFECTIOUS DISEASES
Volume 27, Issue 9, Pages 2349-2359Publisher
CENTERS DISEASE CONTROL & PREVENTION
DOI: 10.3201/eid2709.210934
Keywords
-
Categories
Ask authors/readers for more resources
This study found an increase in mucormycosis cases in India during the COVID-19 pandemic, mainly due to inappropriate glucocorticoid use, resulting in a higher mortality rate among mucormycosis patients.
During September-December 2020, we conducted a multi-center retrospective study across India to evaluate epidemiology and outcomes among cases of coronavirus disease (COVID-19)-associated mucormycosis (CAM). Among 287 mucormycosis patients, 187 (65.2%) had CAM; CAM prevalence was 0.27% among hospitalized COVID-19 patients. We noted a 2.1-fold rise in mucormycosis during the study period compared with September-December 2019. Uncontrolled diabetes mellitus was the most common underlying disease among CAM and non-CAM patients. COVID-19 was the only underlying disease in 32.6% of CAM patients. COVID-19-related hypoxemia and improper glucocorticoid use independently were associated with CAM. The mucormycosis case-fatality rate at 12 weeks was 45.7% but was similar for CAM and non-CAM patients. Age, rhino-orbital-cerebral involvement, and intensive care unit admission were associated with increased mortality rates; sequential antifungal drug treatment improved mucormycosis survival. The COVID-19 pandemic has led to increases in mucormycosis in India, partly from inappropriate glucocorticoid use.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available